In the control groups, no expression of CTGF (IGFBP-rP2) in peripheral MNC was detected, and in the group of adult CML patients only 3.5% (2 of 57) were positive for this gene. The gene discussed is RP2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.